Summary

Eligibility
for people ages 16-26 (full criteria)
Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Amanda Downey (ucsf)
Headshot of Amanda Downey
Amanda Downey

Description

Summary

This is a single site, single dose clinical trial of intravenous (IV) ketamine for medically hospitalized adolescents and young adults with anorexia nervosa or atypical anorexia nervosa. Eating disorder symptoms will be measured pre- and post-ketamine infusion. Investigators hypothesize that ketamine will increase cognitive flexibility, making medical hospitalizations less distressing by improving the ability to learn new, positive associations with food.

Official Title

"KETTLE" Trial: Ketamine Effects on Learning In Eating Disorders

Keywords

Anorexia Nervosa, Atypical Anorexia Nervosa, Anxiety, Depression, Anorexia, Psychotropic Drugs, Feeding and Eating Disorders, Physiological Effects of Drugs, Cognitive Flexibility, Ketamine, Ketamine infusion

Eligibility

Location

  • University of California, San Francisco
    San Francisco California 94158 United States

Lead Scientist at University of California Health

  • Amanda Downey (ucsf)
    Dr. Amanda Downey is a pediatrician and psychiatrist who cares for adolescents and young adults with eating disorders. She works with patients and their families to develop a treatment plan that honors their unique strengths and challenges.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Amanda Downey, MD
ID
NCT06736769
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 20 study participants
Last Updated